Pfizer opened a $68.5 million clinical manufacturing facility in December of 2021 in Durham. Accommodating the company's BioTherapeutics Pharmaceutical Sciences division, the 85,500-sf project will support the creation of gene therapies for the treatment of hemophilia A, hemophilia B, Duchenne muscular dystrophy, and other diseases. Leveraging single-use bioreactors to enable scalable expansion over time, the structure provides multiple drug substance suites, analytical and microbiology labs, and areas for manufacturing and filling.
Part of an $800 million investment in three gene therapy facilities in North Carolina, the next-generation plant is complemented by late-stage and commercial development activities at Pfizer's Sanford site and a pre-clinical process development hub in Morrisville. Comprising 300,000 sf of production space, the three facilities have a total bioreactor manufacturing capacity of 22,000 liters.